Current Report Filing (8-k)
August 13 2021 - 5:06PM
Edgar (US Regulatory)
0000012239
false
0000012239
2021-08-10
2021-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 10, 2021
AIKIDO
PHARMA INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-05576
|
|
52-0849320
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
One
Rockefeller Plaza, 11th Floor,
New York,
NY
|
|
10020
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
|
Registrant’s
telephone number, including area code: (703) 992-9325
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, $0.0001 par
value
|
|
AIKI
|
|
The Nasdaq Capital Market
|
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On August 10, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), received a staff deficiency notice from The
Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share, failed to comply
with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s
letter advised the Company that, based upon the closing bid price during the period from June 28, 2021 to August 9, 2021, the Company
no longer meets this test.
Pursuant
to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided with a compliance period of 180 calendar days, or February 7,
2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s
common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to February 7, 2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIKIDO PHARMA INC.
|
|
|
|
By:
|
/s/ Anthony
Hayes
|
|
Name:
Title:
|
Anthony
Hayes
Chief Executive Officer
|
Dated:
August 13, 2021
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024